Iron‐related markers are associated with infection after liver transplantation
Though serum iron has been known to be associated with an increased risk of infection, hepcidin, the major regulator of iron metabolism, has never been systematically explored in this setting. Finding early biomarkers of infection, such as hepcidin, could help identify patients in whom early empiric...
Saved in:
Published in | Liver transplantation Vol. 23; no. 12; pp. 1541 - 1552 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.12.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Though serum iron has been known to be associated with an increased risk of infection, hepcidin, the major regulator of iron metabolism, has never been systematically explored in this setting. Finding early biomarkers of infection, such as hepcidin, could help identify patients in whom early empiric antimicrobial therapy would be beneficial. We prospectively enrolled consecutive patients (n = 128) undergoing first‐time, single‐organ orthotopic liver transplantation (OLT) without known iron overload disorders at 2 academic hospitals in Boston from August 2009 to November 2012. Cox regression compared the associations between different iron markers and the development of first infection at least 1 week after OLT; 47 (37%) patients developed a primary outcome of infection at least 1 week after OLT and 1 patient died. After adjusting for perioperative bleeding complications, number of hospital days, and hepatic artery thrombosis, changes in iron markers were associated with the development of infection post‐OLT including increasing ferritin (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.12‐2.05), rising ferritin slope (HR, 1.10; 95% CI, 1.03‐1.17), and increasing hepcidin (HR, 1.43; 95% CI, 1.05‐1.93). A decreasing iron (HR, 1.76; 95% CI, 1.20‐2.57) and a decreasing iron slope (HR, 4.21; 95% CI, 2.51‐7.06) were also associated with subsequent infections. In conclusion, hepcidin and other serum iron markers and their slope patterns or their combination are associated with infection in vulnerable patient populations. Liver Transplantation 23 1541–1552 2017 AASLD. |
---|---|
Bibliography: | See Editorial on Page This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant K23 DK083504 to Jennifer K. L. Chow), the Natalie V. Zucker Research Center for Women Scholars at Tufts University School of Medicine (to Jennifer K. L. Chow), and the National Center for Advancing Translational Sciences (grant UL1TR001064). 1499 Mark E. Westerman reports being a scientific cofounder, consultant, and shareholder of Intrinsic LifeSciences. Tomas Ganz reports being a scientific cofounder, consultant, and shareholder of Intrinsic LifeSciences; a scientific cofounder, consultant, and grant recipient for Merganser Biotech; a scientific cofounder, consultant, and grant recipient for Silarus Pharma; and a consultant and grant recipient for Keryx Pharma. David R. Snydman reports being on advisory boards for Merck, Takeda, Shire, Summit, Chimerix, and Seres Therapeutics and being a grant recipient from Merck, Summit, Actelion, Tetraphase, and Seres Therapeutics. The remaining authors of this manuscript report no potential conflicts. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1527-6465 1527-6473 |
DOI: | 10.1002/lt.24817 |